Session Abstract – PMWC 2025 Silicon Valley

Showcase Track S1 - February 5 9.00 A.M.-3.45 P.M.,Showcase Track S1 - February 6 9.45 A.M.-4.00 P.M.,Showcase Track S1 - February 7 11.15 A.M.-2.00 P.M.


The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.


Confirmed Presenting Companies:

 Speaker Profile

M.D., Chief Medical Officer of Oncology, Tempus

Biography
Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as the HematologyOncology Fellowship Program Director.


Talk
Harnessing Tempus Data and AI Platforms for Healthcare Solutions
Uncover how Tempus harnesses vast datasets to help empower providers, accelerate pharma research, and refine management practices, driving the future of personalized medicine.


AI and Data Sciences Showcase:
Tempus

Tempus is a technology company leading the adoption of Al to advance precision medicine and patient care.

 Speaker Profile

Head of Products & Platform (BioStrand), IPA

Biography
Arnout Van Hyftes journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.


AI and Data Sciences Showcase:
ImmunoPrecise (IPA)

ImmunoPrecise is a biotherapeutic research hub leveraging systems biology, multiomics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies. Combining an AI driven approach with best-in-class laboratory capabilities creates a powerful synergy that is revolutionizing antibody discovery.

 Speaker Profile

M.D., Ph.D., FSCCT, Co-founder & CEO, Segmed

Biography
Physician, epidemiologist, biomedical engineer, scientist, and entrepreneur, dedicated to optimizing healthcare by translating clinical needs into technical solutions. Previously, led the clinical cardiovascular imaging research group at Stanford Radiology.His clinical and research background allows to identify and address medical shortcomings effectively. Beyond his technical expertise, he has leadership with various international scientific organizations and co-directs educational courses. With over 100 peer-reviewed papers published, 30 international lectures presented, and funding received from prestigious entities, he holds the title of Fellow of the Society of Cardiovascular Computed Tomography (SCCT). His work, acknowledged through numerous awards, reflects significant contributions to the fields of radiology and cardiovascular imaging.


AI and Data Sciences Showcase:
Segmed

Segmed aims to transform healthcare research by extracting valuable information from medical imaging studies for innovative applications. Our platform facilitates global cohort identification, secure extraction, de-identification, and transfer of targeted studies. Linking images to clinical data support research, AI-imaging, disease diagnosis, and treatment.

 Speaker Profile

Ph.D., Director, Clinical Partnerships, Realyze Intelligence

Biography
Kathryn has dedicated her career to advancing patient-centric approaches to healthcare. Currently her passion lies in leveraging human-in-the-loop AI to bridge the gap between clinical research and patient care. While her graduate work was in microbiology she is currently hyper-passionate about precision oncology. She is actively working towards a future where data silos are a stumbling block of the past where all patients have the opportunity to participate in research as care.


Talk
Understanding the Whole Patient Story, in Real Time
Learn how the Realyze platform unlocks clinical insights from the patient record to drive precision medicine. Hear how our partners are already using these insights to accelerate scale clinical trial screening, build powerful clinico-genomic databases, monitornudge clinical pathway adherence, and turbocharge complex, RWD data dependent research pursuits.


AI and Data Sciences Showcase:
Realyze Intelligence

Realyze Intelligence uses a validated combination of clinical knowledge & human-in-the-loop AI to abstract rich, real-world data summarized at the patient level. We recognize that data is the fuel that drives precision medicine - our goal is to empower clinicians & researcher to rapidly accelerate precision medicine.

 Speaker Profile

Ph.D., A. Melvin Ramsay Fellow (Former Chief Scientific Officer), Solve M.E.

Biography
Tim advises Solve M.E. on data, AI, and research strategy to advance precision medicine for MECFS, Long COVID, and other post-infection diseases. He is an author and reviewer for the JCO Clinical Cancer Informatics and a member of the NINDS MECFS Biospecimen Resource Access Committee. Previously, Tim oversaw research funding at both the American Society for Radiation Oncology and the NIH. He has been recognized by awards such as the NIH Directors Award, NCATS Directors Award, NIAID Merit Award, the U.S. Department of State Embassy Science Fellowship, and the American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellowship.


Talk
Catalyzing a RWD Strategic Alliance for Precision Medicine
National Academy of Medicine recommended a common research agenda for infection-associated chronic conditions and illnesses (IACCIs). We will showcase Solve M.E.'s RWD platform, with case studies on how the platform helped explore IACCI patient subtyping and trial recruitment, and also discuss the vision to catalyze a RWD strategic alliance to advance IACCI precision medicine.


AI and Data Sciences Showcase:
Solve M.E.

The Solve ME/CFS Initiative (Solve M.E.) is a non-profit organization that serves as a catalyst for critical research into diagnostics, treatments, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid and other post-infection diseases.

 Speaker Profile

Founder & CEO, Magna Labs

Biography
Gwenn Berry is the founding engineer and CEO of Magna Labs Inc., whose mission is to accelerate the innovation and delivery of precision science medicine by empowering scientists to build and test high-quality bioinformatics tools. Gwenn has over a decade of experience in applying and adapting software best practices to bioinformatics algorithm development and transitioning research software into both commercial research-use-only (RUO) and in-vitro diagnostic (IVD) on-market products in the genomics industry. Her work specializes in production-grade bioinformatics algorithm and pipeline development, including methods evaluation and optimization, novel methods development, verification and validation, and remediation of prototype or research-grade software for commercial and clinical readiness.


Talk
Automating Bioinformatic Software Validation for Production-grade Development
Bioinformatics software drives omics research and development, yet comprehensive software QA is often ad hoc, manual and time-intensive. Miqa, a no-code, cloud-enabled QA automation platform, continuously tests and benchmarks bioinformatic algorithms, ensuring development speed, analytical accuracy, and data reproducibility to transform genomic information into actionable insights for precision medicine.


AI and Data Sciences Showcase:
Magna Labs

Magna Labs provides software quality assurance (QA) solutions to support the safe development and evaluation of bioinformatic software for precision therapeutics and diagnostics. Our software tools help scientists easily incorporate software testing best practices into their workflows, improving the quality and speed of scientific innovations.

 Speaker Profile

Ph.D., CEO, L7 Informatics

Biography
Vasu Rangadass, Ph.D., is the CEO of L7 Informatics, a company that delivers software and services enabling DATA+INTELLIGENCE for science and health. Since joining L7, Dr. Rangadass has led the further development of the Enterprise Science Platform (L7ESP), a cutting-edge scientific process and data management solution that empowers life science and healthcare organizations to connect people, processes, and systems, accelerating discoveries and advancing precision healthcare.Prior to L7 Informatics, Dr. Rangadass served as Chief Strategy Officer at NantHealth, following its acquisition of Net.Orange, the company he founded. Net.Orange provided an enterprise-wide platform, the Clinical Operating System (cOS), designed to simplify and optimize care delivery processes within health systems. With a rich background in digital health and a passion for transforming healthcare through innovative technology, Dr. Rangadass continues to lead initiatives that drive impactful change in the industry.


Talk
Orchestration Platforms: The Key for Enterprise Knowledge Generation and Intelligence
Explore how orchestration platforms serve as the foundation for AI-ready data contextualization and real-time intelligence in life sciences. L7's CEO, Vasu Rangadass, Ph.D, and team highlights the transformative potential of digital orchestration platforms in creating departmental & Enterprise knowledge graphs and driving Artificial intelligence models.


AI and Data Sciences Showcase:
L7 Informatics

L7 Informatics, Inc. is a leading provider of integrated scientific data and analytics solutions. The company offers a comprehensive platform that enables seamless data integration, advanced analytics, and collaborative workflows, empowering scientists and researchers to accelerate discoveries, improve operational efficiencies, and drive innovation.

 Speaker Profile

CTO and Co-founder, PointHealth AI

Biography
Rachel Gollub founded her current company to bring together patient medical history, social determinants of health, and genomic data to bring secure precision medicine to patients everywhere. A Silicon Valley inventor and entrepreneur with a degree from Caltech, she started her career on the team inventing the Java language, later moving to Stanford University to design and build the Stanford Digital Repository. Since then, she has been founding companies to leverage the latest technologies. Most recently, she left a position as CTO of the UnitedHealthcare Technology Employer Individual division to leverage her AI and machine learning background to build a startup at the heart of precision medicine.


Talk
Precision Medicine through Reinforcement Learning
PointHealth AI uses reinforcement learning to bring together several aspects of patient data to determine the best course of treatment for a specific patient at the point of diagnosis. Here's how we do it.


AI and Data Sciences Showcase:
PointHealth AI

PointHealth AI brings together medical history, social determinants of health, and genomics to bring better courses of treatment to patients. We give providers on-the-spot recommendations from our data analyses to help patients at the point of diagnosis.

 Speaker Profile

Ph.D., CEO and Co-Founder, Prism AI Therapeutics

Biography
Experienced entrepreneur, scientist, and executive with over 20 years of product development, business development, and team management in the defense and life science industries. Previously, Dr. Zviran was the Co-Founder, CEO CSO of C2i Genomics, leading the company from an academy spin-off to a global commercial leader and to a successful exit. As a former cancer survivor, Asaf is committed to improving cancer patients' quality of life and outcomes.


Talk
Solving the Small and Noisy Multi-Omics Data Problem
We will present an end-to-end solution for the development of AI-driven precision therapeutics. Our quantum-based AI/ML is uniquely able to discover mechanistically interpretable disease models, and correctly discover biomarkers and drug targets. All from small-cohort, real-life and noisy, high-dimensional multi-omics clinical data. Our platform provides a comprehensive end-to-end service, encompassing global sourcing of clinically annotated biospecimens and molecular lab processing with federated-learning insight generation.


AI and Data Sciences Showcase:
Prism AI Therapeutics

Prism AI uses quantum mechanics-based AI/ML to accelerate the development of precision therapeutics for our biotech customers.

 Speaker Profile

M.D., Ph.D., VP, Head of Discovery Biology and Early Clinical Development, Octant Bio

Biography
Matthew Albert is currently at Octant Bio, where he focuses on integrating translational medicine and innovative approaches to drug discovery and development. His work centers on harnessing advanced biomarker strategies, human genetics and functional genomics-driven insights to address rare diseases, with a commitment to making personalized medicine a reality. At Octant, Matthew collaborates across scientific disciplines, aiming to transform therapeutic approaches by combining small molecule corrector therapies with cutting-edge platform technologies. He leverages his extensive experience in human genetics and translational research to guide teams in developing next-generation therapies. Matthew's vision is anchored in the belief that accelerated innovation and personalized solutions are key to addressing unmet medical needs.


Talk
Unlocking Human Genetics for Precision Clinical Trials
At Octant Bio, we leverage deep mutational scans and genetic data to develop targeted small molecule therapies. By defining mechanistic insight into response to corrector therapy, we optimize strategies that advance precision medicine for genetic disorders. Our lead program focuses on Rhodopsin-associated Retinitis Pigmentosa (RHO-adRP), providing hope for approximately 50% of patients with amenable mutations.


Large-scale Data Solutions Showcase:
Octant Bio

Octant Bio is a biotechnology company using cutting-edge technologies to develop precision medicines. By combining synthetic biology, data-driven insights, and nano-scale high-throughput chemical screens, Octant is transforming drug discovery with the aim to improve patient outcomes across multiple therapeutic areas.

 Speaker Profile

Ph.D., CEO, Diagnostic Robotics

Biography
Dr. Kira Radinsky is an accomplished computer scientist, entrepreneur, and keynote speaker. She was born in Ukraine in 1986 and moved with her family to Israel at the age of four. Radinsky showed an early aptitude for mathematics and computer science, and by the age of 16, she was studying at the Technion - Israel Institute of Technology. She was awarded the prestigious Google Europe Fellowship in Social Computing for her groundbreaking work in data mining and natural language processing and founded SalesPredict, a predictive analytics startup that uses machine learning algorithms to help businesses forecast future sales. The company was acquired by eBay in 2016, and Radinsky continued to work with eBay as its director of data science until 2017. She has since founded Diagnostic Robotics, a healthcare analytics solution company focused on using machine learning and other advanced technologies to make healthcare more efficient, effective, and accessible.


Talk
Advancing Ethical AI in Proactive Care
Care providers are constantly asked to do more with less. Carefully and thoughtfully using the latest in predictive analytics, and combining that with tools that automate manual processes (such as data mining, outreach prioritization, and information gathering) can help bring joy back to working in healthcare, address staffing challenges, and make care more proactive.


AI and Data Sciences Showcase:
Diagnostic Robotics

Diagnostic Robotics exists to bring trusted, leading edge, proactive analytics and tools to healthcare. We’re a clinician’s trusted resource to relieve administrative burdens, improve staffing ratios, reduce cost of care, and improve patient experiences.

 Speaker Profile

JD,MBA, CEO and Co-Founder, Archetype Tx

Biography
Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug discovery and repurposing in cancer and other diseases. The Archetype platform enables virtual phenotypic screening of billions of molecules per day for their effect on clinical outcomes in cohorts of patients with unmet medical need. Previously Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company. He was also a member of the founding team and Executive Vice President, Corporate Development at the causal AI drug discovery company Aitia. After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence Haug LLP. He started his career after his undergraduate chemical engineering studies as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little.


Talk
Diagnostics Driven Drug Discovery Using Generative Chemogenomics
Validated clinical genomic tests built using real world outcome data effectively predict poor patient outcomes. Generative chemogenomics virtually tests the ability of billions of compounds to reverse the molecular fate of patients with poor predicted outcomes. New drug candidates and insights into existing drug programs are generated without waiting years for outcomes.


AI and Data Sciences Showcase:
Archetype Therapeutics

Archetype Therapeutics is an AI-native biotech company that is with its Archetype™ platform pioneering the use of generative chemogenomics and patient clinicogenomic data to enable the virtual screening of billions of potential drugs per day.

 Speaker Profile

MSc, Chief Executive Office, Ibex Medical Analytics

Biography
aJoseph Mossel is CEO and Co-Founder of Ibex Medical Analytics. Together with Co-Founder and CTO Chaim Linhart, he embarked on a journey to transform cancer diagnostics by empowering pathologists with AI insights that help them improve diagnostic accuracy, efficiency and turnaround times. His career in the tech industry spans more than 20 years, starting off in software development and product management followed with leadership positions in startups and large multinational corporations where he has led products from inception all the way to maturity as multi-million-dollar businesses. Joseph has also held a tenure in the non-profit sector, serving as managing director of Israels National Ecosystem Assessment Program.Joseph holds an MSc in computer science from Tel Aviv University, and an MSc in environmental science from VU Amsterdam. He is an alumnus of the Adi Lautman Interdisciplinary Program for Outstanding Students at Tel Aviv University.


Talk
AI in Cancer Diagnostics: Real World Learnings
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI-powered solutions for pathology. Deployed globally in routine clinical use, this session will cover key learnings from Ibexs vast customer usage, strategic industry partnerships and collaboration with pharmaceutical and biotechnology companies to enable precision medicine.


AI and Data Sciences Showcase:
Ibex Medical Analytics

Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI powered solutions for pathology. Empowering clinicians and pathologists, Ibex strives to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology.

 Speaker Profile

Ph.D., Director, Research Services, Zymo

Biography
Keith Booher has been involved in the biotech sector for 15 years taking on various scientific, business development, and leadership roles. In his current position at Zymo Research, Keith leads the professional research services team, which primarily utilizes NGS technology to answer questions in the field of genomics especially, microbiome, epigenome, and transcriptome focused analysis. In addition, Keith is the Principal Investigator on over $12 million in research grants and contracts from various federal and local entities. Keith is particularly interested in multi-omics approaches that utilize advanced sample prep, cutting edge sequencing, and Artificial Intelligence or Machine Learning tools to help solve the most challenging problems in molecular biology.


Talk
Simple, Custom Workflows to Empower AI-Driven Drug Prediction
A simple, efficient sample collection and gene expression analysis workflow enables scalable transcriptome data generation to power a probabilistic network model of human health that can identify small molecules able to restore a disease back to a healthy state. The platform has already identified re-purposed drugs for rare disease patients with very limited treatment options.


AI and Data Sciences Showcase:
Zymo

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo is dedicated to developing innovative solutions that address complex scientific challenges.

 Speaker Profile

Other, Head of Global Business Development, Axcelead Group

Biography
AI RD for drug discovery service. Axcelead is a CROCDMO spin-off startup from Takeda based in Japan with presence globally. The AI RD team is developing foundation models for drug discoveries utilizing both open source and proprietary models for insilico with validation for lab in the loop automation in Japan. Previous founder of Stanford spinoff for AI and genomics company focused on common complex diseases with focus on cardiac and CNS diseases. Degrees from Stanford and University of Chicago.


Talk
Comparative Foundation Model Approaches for Modeling ADMET Properties
In drug discovery, AI is also making an impact in protein structure predictions but there are still challenges for adoption in ADMET properties predictions. We explore a comparison between two of the most recent leading deep learning models, graph neural network (GNNs) and transformer based models to test their accuracy with our proprietary large-scale data.


AI and Data Sciences Showcase:
Axcelead Group

Axcelead is a leading Japanese biotech company spun out from Takeda with global partners. Our team includes hundreds expert chemist and AI to help our partners with insilico to wetlab validation in end to end services integrating the latest modelling techniques in AI.

 Speaker Profile

CEO & Co-Founder, Aganitha AI

Biography
As a co-founder of Aganitha, Vikram has been engaged with global biopharma to bring innovations in Machine Learning and AI to drug discovery. Aganitha is focused on accelerating drug discovery and development using the power of deep science and deep tech. An early AI researcher at IIT Bombay and UC Santa Cruz, Vikram is a serial entrepreneur and a founder of multiple Silicon Valley startups. He previously served as Chief Technologist Head of Enterprise Transformation at HCL Technologies a global technology services company. He holds several patents in analytics and data management.


Talk
Beyond the Hype - AI Case Studies Accelerating Biopharma RD
Our case studies illustrate how generative AI & in silico modeling mine insights from deep science enabled by high-throughput and single-cell methods to transform disease research, therapeutic design, trial design & indication expansion.This delivers better targets and biomarkers, faster design, characterization & optimization of therapeutics (SMOLs, Antibodies, ASOs & ACGTs), smart cohorts, companion diagnostics and effective end points.


AI and Data Sciences Showcase:
Aganitha AI

Aganitha partners with global pharma to bring novel medicines to market faster. Physics based chemistry, omics enriched biology, generative AI based drug design and tech innovations power our offerings in oncology, auto-immune disorders, CNS disorders, rare genetic disorders, metabolic disorders, and infectious diseases.

 Speaker Profile

M.D., Healthcare Executive Advisor, AWS

Biography
Rod Tarrago, MD leads clinical informatics for academic medicine at AWS. He has 15 years of experience as a CMIO at two pediatric healthcare systems and was a pediatric critical care physician for 20 years.


Talk
AI-Driven Advances in Neglected Healthcare Areas
AI is changing the world of healthcare at a rapid pace. Given the excitement, we often focus on "new shiny objects" and risk ignoring crucial but less flashy opportunities. I will discuss areas where AI can help healthcare organizations make a major impact on patient safety, clinician and patient experience, and finances.


AI and Data Sciences Showcase:
AWS

 Speaker Profile

M.D., Ph.D., Co-Founder and Chief Scientific Officer, Genomenon

Biography
Dr. Mark Kiel completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He is the founder and chief scientific officer at Genomenon, a genomic intelligence company, where he oversees the company's scientific direction and product development. Mark founded Genomenon in 2014 to address the challenge of connecting researchers with evidence in the genomic literature to help diagnose and treat patients with genetic diseases and cancer.


Talk
Unlocking Genomic Insights: Harnessing AI for Breakthroughs
Dr. Mark Kiel discusses the challenges of integrating AI in genomics and its transformative possibilities. With AI-driven analysis of comprehensive genomic data, researchers can uncover hidden patterns, predict disease trajectories, and personalize treatments, pushing forward the frontiers of genomic intelligence.


AI and Data Sciences Showcase:
Genomenon

Genomenon is a genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights.

 Speaker Profile

Ph.D., Chief Scientific Officer, Modella AI

Biography
Max Lu leads the company's research in multimodal and generative AI for medicine and healthcare. He earned his PhD in Computer Science from MIT, where he conducted pioneering work in computational pathology advised by Professor Faisal Mahmood. Max has driven the development of multiple impactful AI tools, including large-scale vision and vision-language pretrained foundation models, algorithms for clinical endpoint prediction from HE histology slides, and PathChat, a multimodal generative AI copilot for human pathology. His research contributions have been published in leading journals and conferences including Nature, Nature Medicine, and CVPR.


Talk
Advancing Pathology and Healthcare with Generative and Agentic AI
Discover how Modella AI enables customers to transform biomedical image analysis and research through multimodal foundation models, generative and agentic AI.


AI and Data Sciences Showcase:
Modella AI

Modella AI is a biomedical artificial intelligence company based in Boston, Massachusetts. We are an interdisciplinary team of scientists, clinicians, and AI researchers working together in developing and deploying intelligent systems that improve healthcare delivery and outcomes.

 Speaker Profile

Ph.D., Advisory Board Member, Compass Bioinformatics

Biography
Scott Kahn joined the Board of Directors at Exagen after serving as the Chief Information and Privacy Officer at LunaPBC where he was responsible for all informatics and data science strategy. Through his work with the Helmsley Charitable Trust, Scott has worked on data privacy and data sharing policies for biomedical organizations globally, and he serves on the Board of Directors for Rady Childrens Institute of Genomic Medicine and is the Chairman of the Board for Blue Circle Health. Previously Scott spend 11 years as Illumina's first Chief Information Officer, and he also was an executive leader in Illumina's Enterprise Informatics Unit. He organized the Genome Informatics Alliance for five years to drive interdisciplinary thought leadership focused on the future of Next Generation Sequencing (NGS) and its role in precision medicine, healthcare, and other applied markets.Scott was a Fellow Commoner of Churchill College at the University of Cambridge in England.


Talk
AI, -OMICs, and Precision Medicine
Clinical interpretation of variants generated by NGS are the foundation of genome based diagnostics. With the advance of machine learning techniques, automated, accurate, and efficient interpretation of variants expands the utility of clinical sequencing for broader diagnostics and development of therapeutics. We present the evolution of the InheriNext platform to solve for the current opportunity.


AI and Data Sciences Showcase:
Compass Bioinformatics

COMPASS BIOINFORMATICS INC. was founded by a team of engineers, scientists, and medical professionals. The primary focus of our genomic analysis software is accuracy, and we deliver accuracy with scalability, efficiency and simplicity.

 Speaker Profile

Ph.D., Chief Technology Officer, DNAnexus

Biography
Part of DNAnexus since its inception, George has been involved in the design and implementation of the DNAnexus product line and its application in key accounts around the world. He currently heads strategic projects, exploring ways in which DNAnexus technology can be used to craft novel experiences that transcend traditional genomics boundaries. George holds a PhD in computer science from Stanford University, where he helped analyze 1% of the human genome as part of the ENCODE Pilot Project. His prior research experience includes comparative metagenomics, silicon compilers for reconfigurable hardware, and elliptic curve cryptanalysis.


Talk
Clinico-Genomic Data Enablement for the GenAI Era
Discover how enriched, fine-grain clinico-genomic data and comprehensive associated metadata enable powerful data science workflows and seamless integration with generative AI models.


AI and Data Sciences Showcase:
DNAnexus

DNAnexus, the enterprise platform for precision health, is on a mission to accelerate the development, approval and delivery of personalized treatments. DNAnexus powers a flexible, connected ecosystem that makes omics and real-world data accessible, actionable, and secure. Visit www.dnanexus.com or @DNAnexus.

 Speaker Profile

CEO, Tunld

Biography
Clynt Taylor is co-founder and CEO of Tunld, Inc., a new AI-powered precision oncology informatics platform. He has been an innovator in healthcare for over 35 years, as an entrepreneur and senior executive with startup and growing companies. Most recently he served as CEO of Trapelo Health, Inc., an oncology decision support company later acquired by NeoGenomics in 2021. He assumed the role of NeoGenomics Informatics Division president until 2023 when he left to launch Tunld, Inc. Since beginning his career at IBM, hes held various leadership roles at healthcare technology companies including NextGen, HealthVision and at Galvanon Healthcare Solutions as Co-founder and CEO (purchased by NCR). He also held senior executive roles with Eviti, Inc. and with NantHealth, including as Sr. VP of Marketing leading the launch and commercialization of GPS Cancer, a first-of-its-kind, comprehensive test that integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics.


Talk
Bringing Your Data to Life
Your healthcare data can be messy, inconsistent, illegible, even incoherent. But its gold if you can mine it, something exceedingly hard to do at scale. Tunld brings your data to life. Ingesting thousands of documents in all formats, Tunld identifies, parses, normalizes and contextualizes into discrete forms giving you a powerful new data asset.


AI and Data Sciences Showcase:
Tunld

Tunld uses a symphony of multiple technologies to transform static documents into valuable clinical discrete data - at scale.

 Speaker Profile

M.D., Professor and Division Head, OHSU

Biography
Dr. Shivaani Kummar is Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, and Deputy Director for Clinical and Translational Research, Knight Cancer Institute, Oregon Health Science University, Portland, Oregon, USA. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. She is a member of scientific planning committees of national and international professional organizations and has authored over 160 peer reviewed publications, 9 book chapters, and co-edited a book on Novel Designs of Early Phase Trials for Cancer Therapies. She is currently a member of the American Association for Cancer Research Exploratory INDPhase 0 Clinical Trials Task Force, and co-Chair of the Clinical Trials Committee, AACR Annual Meeting 2023-2024.


Talk
AI-powered Multi-omics Platform to Advance Precision Medicine
PATHOMIQ's AI-powered tests analyze cancer diagnostic tissue images to predict treatment response to various cancer treatments. It also identifies specific tissue regions that harbor cancer driver(s). These regions yield known or new targets in each patient for development of personalized therapies and efficacious medicine.


AI and Data Sciences Showcase:
OHSU

PATHOMIQ, a technology company, has developed an AI powered multi-omics platform that can accurately predict cancer treatment response from tissue images. These AI enabled tests can inform treatment decisions for a given patient as well as identify novel targets for drug development.

 Speaker Profile

Ph.D., CTO Innovation, Assuta Medical Center

Biography
Yochai Edlitz is the Chief Technology Officer at the Innovation Department of Assuta Ashdod Medical Center, where he leads the integration of AI and machine learning to improve healthcare services and efficiency. Founder of MLAIA Data Science Ltd., delivering advanced solutions in AI, data science, and signal processing.A veteran officer of an elite IDF technology unit, Yochai has a proven history of developing transformative technologies across industries. His achievements include predictive healthcare models, business intelligence tools, and innovative digital signal processing solutions. With deep technical expertise and strategic leadership, Yochai is dedicated to turning complex challenges into impactful, practical innovations.


Talk
AI-Driven Personalized Support for Hospitalization and Recovery
This presentation showcases an AI-driven tool supporting personalized hospitalization and recovery. It provides a personal assistant, tracks rehabilitation progress, and offers tailored community resources. Designed for patients, families, caregivers, and institutions, it enhances collaboration, streamlines care, and empowers holistic recovery through advanced AI capabilities and real-time insights.


AI and Data Sciences Showcase:
Assuta Ashdod

Established in 2017, Assuta Ashdod Medical Center is a university hospital serving the southern Israel community. Combining advanced technologies with multidisciplinary expertise, it delivers high-quality healthcare, fosters innovation, and conducts groundbreaking research to enhance patient care and support regional medical excellence.

 Speaker Profile

Ph.D., CEO and CSO, Phinomics

Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative company transforming precision medicine by unlocking the potential of circular DNA and integrating genomics with advanced AI. With dual PhDs in Molecular Biology and Biomedical Engineering, Massa has over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fires lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships, including the Arnold O. Beckman Fellowship, and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology solutions through the Circulome Atlas, a transformative platform providing unparalleled insights into cancer etiology, progression, and therapeutic resistance.


Talk
Leveraging Circulome Data and AI for Precision Oncology
Discover how Phinomics leverages the power of circular DNA and the Circulome Atlas, using advanced AI approaches to mine this unique resource for first-in-class biomarkers and therapeutic targets. Learn how our platform accelerates discovery, empowers precision oncology, and drives the future of personalized medicine with transformative insights into cancer biology.


AI and Data Sciences Showcase:
Phinomics

Phinomics is revolutionizing precision medicine by harnessing the power of circular DNA to uncover novel biomarkers, accelerate therapeutic discovery, and deliver unparalleled insights into cancer biology and other diseases.

 Speaker Profile

Ph.D., Co-Founder & CEO, Aikium

Biography
Eswar Iyer is the Co-founder and CEO of Aikium Inc., a therapeutics company pioneering new treatments with Yotta-ML², the world’s first AI-driven trillion-protein wet lab screening platform. With over 100 patents spanning single-cell and spatial multiomics, protein and tissue engineering, hardware, and AI, Eswar has dedicated his career to advancing high-definition biological design and discovery. He completed a postdoc with George Church at Harvard’s Wyss Institute, working on groundbreaking synthetic biology approaches, and holds a PhD from George Mason University. His innovations have driven multiple industry-defining platforms and strategic acquisitions totaling $480 million. Today, Eswar leads Aikium in developing targeted protein therapeutics for diseases with significant unmet needs, focusing on areas where traditional approaches like antibodies and small molecules fall short.


Talk
Worlds First AI-Powered Trillion-Protein Screening: Unlocking the Undruggable Proteome


AI and Data Sciences Showcase:
Aikium

Aikium is revolutionizing therapeutics with Yotta-ML², the world’s first AI-driven trillion-protein screening platform. By unlocking undruggable targets where antibodies and small molecules fail, Aikium pioneers next-generation protein therapeutics for cancer, immune disorders, and beyond—pushing the boundaries of AI-powered drug discovery

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by FEB. 13TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required